60 Degrees Pharmaceuticals, Inc.
SXTP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $1 |
| % Growth | 139.6% | 13.6% | -80.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 36.7% | -87.1% | -93.7% | 26.7% |
| R&D Expenses | $5 | $1 | $1 | $6 |
| G&A Expenses | $5 | $4 | $1 | $1 |
| SG&A Expenses | $5 | $4 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 | -$5 |
| Operating Expenses | $10 | $5 | $2 | $1 |
| Operating Income | -$10 | -$5 | -$2 | -$1 |
| % Margin | -1,599% | -2,032.8% | -784.2% | -96.9% |
| Other Income/Exp. Net | $2 | $1 | -$4 | -$3 |
| Pre-Tax Income | -$8 | -$4 | -$6 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$4 | -$6 | -$4 |
| % Margin | -1,308% | -1,485.1% | -2,769.5% | -366.4% |
| EPS | -18.55 | -0.95 | -1.07 | -0.74 |
| % Growth | -1,852.6% | 11.2% | -44.6% | – |
| EPS Diluted | -18.55 | -0.95 | -1.07 | -0.74 |
| Weighted Avg Shares Out | 0 | 4 | 6 | 6 |
| Weighted Avg Shares Out Dil | 0 | 4 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $2 | $4 | $3 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$1 | -$2 | -$1 |
| % Margin | -1,297.6% | -562.6% | -944.9% | -87.5% |